{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:57:10Z","timestamp":1760057830694,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET\/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET\/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET\/CT imaging was performed using a 5-ring Discovery IQ PET\/CT scanner with QClear reconstruction, following the injection of 2.5 MBq\/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 \u00b1 12.4 ng\/mL vs. 18.3 \u00b1 6.7 ng\/mL; p &lt; 0.01) and Gleason scores (median: 8 vs. 6; p &lt; 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 \u00b1 4.3 vs. 3.4 \u00b1 1.2; p &lt; 0.001), and HU values were also higher (mean: 45 \u00b1 15 vs. 18 \u00b1 10; p &lt; 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p &lt; 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p &lt; 0.01). Conclusions: [68Ga]Ga-PSMA PET\/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.<\/jats:p>","DOI":"10.3390\/curroncol32030127","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:36:47Z","timestamp":1740375407000},"page":"127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET\/CT Imaging"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-3174","authenticated-orcid":false,"given":"Ebuzer","family":"Kalender","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Gaziantep University, 27410 Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-5816","authenticated-orcid":false,"given":"Edanur","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Gaziantep University, 27410 Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Elbo\u011fa","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Gaziantep University, 27410 Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertan","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Gaziantep University, 27410 Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, C.-W., Chiang, Y.-C., Vo, T.T.T., Lin, Z.-C., Chi, M.-C., Fang, M.-L., Peng, K.-T., Tsai, M.-H., and Lee, I.T. (2024). Deciphering the Liaison Between Fine Particulate Matter Pollution, Oxidative Stress, and Prostate Cancer: Where Are We Now?. Antioxidants, 13.","DOI":"10.3390\/antiox13121505"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.adro.2024.101670","article-title":"Outcomes and Toxicities After Treatment for Men Diagnosed with Localized Prostate Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis","volume":"10","author":"Donkor","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_4","first-page":"1076","article-title":"MRI-based Radiomics for Predicting Prostate Cancer Grade Groups: A Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies","volume":"12","author":"Lomer","year":"2024","journal-title":"Acad Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor\u2013mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/rg.2020190121","article-title":"Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review","volume":"40","author":"Tanaka","year":"2020","journal-title":"RadioGraphics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JU.0000000000003644","article-title":"Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA","volume":"210","author":"Rowe","year":"2023","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/EJE-18-0296","article-title":"Management of Endocrine Disease: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas","volume":"179","author":"Bourdeau","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5152\/dir.2022.21691","article-title":"Differentiation of adrenal adenomas from adrenal metastases in single-phased staging dual-energy CT and radiomics","volume":"28","author":"Winkelmann","year":"2022","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Odedra, D., Narayanasamy, S., Sabongui, S., Priya, S., Krishna, S., and Sheikh, A. (2022). Dual Energy CT Physics\u2014A Primer for the Emergency Radiologist. Front. Radiol., 2.","DOI":"10.3389\/fradi.2022.820430"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., and Schmid, F.A. (2024). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16.","DOI":"10.3390\/cancers16244263"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11255-017-1541-y","article-title":"New frontiers in prostate cancer imaging: Clinical utility of prostate-specific membrane antigen positron emission tomography","volume":"49","author":"Afaq","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000002457","article-title":"Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen","volume":"207","author":"Kuppermann","year":"2022","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2214\/AJR.20.23912","article-title":"Diagnostic Accuracy of (68)Ga-PSMA PET\/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"216","author":"Satapathy","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14737159.2024.2383439","article-title":"[(68)Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer","volume":"24","author":"Clore","year":"2024","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"RadioGraphics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.117.191882","article-title":"68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling","volume":"58","author":"Young","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108330","DOI":"10.1016\/j.compbiolchem.2024.108330","article-title":"Serum levels of PSA and VEGF2 as the prognosis markers for bone metastasis of prostate cancer: A retrospective study","volume":"115","author":"Zhang","year":"2025","journal-title":"Comput. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00330-020-07318-2","article-title":"Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET\/CT as a new diagnostic avenue","volume":"31","author":"Krishnaraju","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prnil.2020.07.008","article-title":"Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer","volume":"9","author":"Kwan","year":"2021","journal-title":"Prostate Int."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Masselli, G., Sollaku, S., De Angelis, C., Polettini, E., Gualdi, G., and Casciani, E. (2024). 68Ga-PSMA PET\/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0. Diagnostics, 14.","DOI":"10.3390\/diagnostics14121291"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1177\/0284185119830292","article-title":"Distinguishing metastases from benign adrenal masses: What can CT texture analysis do?","volume":"60","author":"Shi","year":"2019","journal-title":"Acta Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz, P., Ku\u010dera, P., \u010ctvrtl\u00edk, F., Langov\u00e1, K., Hartmann, I., and T\u00fcd\u00f6s, Z. (2020). Diagnostic Value of Unenhanced CT Attenuation and CT Histogram Analysis in Differential Diagnosis of Adrenal Tumors. Medicina, 56.","DOI":"10.3390\/medicina56110597"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ird3.95","article-title":"Clinical applications, safety profiles, and future developments of contrast agents in modern radiology: A comprehensive review","volume":"2","author":"Najjar","year":"2024","journal-title":"iRADIOLOGY"},{"key":"ref_25","first-page":"1","article-title":"Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT\/CT with xSPECT Quant: Prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone","volume":"11","author":"Robertson","year":"2024","journal-title":"La Radiol. Medica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12149-021-01606-7","article-title":"Diagnostic efficiency of hybrid imaging using PSMA ligands, PET\/CT, PET\/MRI and MRI in identifying malignant prostate lesions","volume":"35","author":"Scobioala","year":"2021","journal-title":"Ann. Nucl. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:03Z","timestamp":1760028063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030127"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030127","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,2,23]]}}}